News

The CRL is consistent with the preliminary feedback Cosmo announced on May 9, 2018, stating that the FDA identified unspecified deficiencies that preclude the continuation of the discussion

The company received series A funding under the round led by Oxford Sciences Innovation (OSI), and the participants include Neptune, RT Ventures, GT Healthcare, Tanarra, Fushia and personal

The deal is expected to fetch about $520m to the US-based Cara Therapeutics. The licensing of Korsuva, an anti-itching and anti-pain injection, with VFMCRP will be only for

The shareholding is to be acquired in an all-cash, combined Stock Purchase Agreement by Takeda’s joint venture partner in Techpool: Shanghai Pharmaceutical Holding Co. Ltd. (Shanghai Pharma SSE

The investigational oral treatment would be used in addition to insulin therapy to improve blood sugar control in adults with type 1 diabetes. Sanofi development global head and

The Singapore Economic Development Board is supporting the development of new facility, which is the firm’s first abroad site in Asia and second site outside of China. The

The partnership uses Evotec's phenotypic screening capabilities and compound libraries. According to the terms of the long-term drug discovery and development partnership, Celgene will pay an upfront payment of

The patents, among other aspects, broadly cover compositions of matter of the inflammation-targeting microfiber materials with embedded molecules of interest. The platform is being evaluated for use across

Juluca is a two-drug regimen of ViiV Healthcare’s dolutegravir and Janssen Sciences Ireland’s rilpivirine. The drug received approval to treat HIV-1 infection in adults, who are virologically suppressed (HIV-1